• CVS Group maintained highest-priority critically important antimicrobial prescriptions at 1.5% of companion animal consultations, below its 2% benchmark.
• The group will retain its below-2% benchmark during 2026-27, prioritizing clinically appropriate prescribing rather than further reductions.
• Practice-level stewardship action plans will be embedded across the organization, with evaluation of their impact on prescribing behaviors beginning during the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVS Group plc published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.